X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Unichem Lab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs UNICHEM LAB - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD UNICHEM LAB MERCK LTD/
UNICHEM LAB
 
P/E (TTM) x 34.2 29.9 114.3% View Chart
P/BV x 3.8 3.1 121.5% View Chart
Dividend Yield % 0.7 0.6 122.6%  

Financials

 MERCK LTD   UNICHEM LAB
EQUITY SHARE DATA
    MERCK LTD
Dec-16
UNICHEM LAB
Mar-16
MERCK LTD/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,060334 317.4%   
Low Rs623174 358.0%   
Sales per share (Unadj.) Rs632.4146.9 430.5%  
Earnings per share (Unadj.) Rs45.711.9 384.4%  
Cash flow per share (Unadj.) Rs62.316.2 385.0%  
Dividends per share (Unadj.) Rs11.002.00 550.0%  
Dividend yield (eoy) %1.30.8 166.0%  
Book value per share (Unadj.) Rs388.8105.1 369.9%  
Shares outstanding (eoy) m16.6090.84 18.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.31.7 77.0%   
Avg P/E ratio x18.421.4 86.2%  
P/CF ratio (eoy) x13.515.7 86.1%  
Price / Book Value ratio x2.22.4 89.6%  
Dividend payout %24.116.8 143.1%   
Avg Mkt Cap Rs m13,96923,073 60.5%   
No. of employees `0001.65.7 27.9%   
Total wages/salary Rs m1,4872,558 58.1%   
Avg. sales/employee Rs Th6,631.92,352.5 281.9%   
Avg. wages/employee Rs Th939.2450.9 208.3%   
Avg. net profit/employee Rs Th479.4190.4 251.7%   
INCOME DATA
Net Sales Rs m10,49813,346 78.7%  
Other income Rs m242192 126.3%   
Total revenues Rs m10,74113,538 79.3%   
Gross profit Rs m1,1351,639 69.3%  
Depreciation Rs m276390 70.6%   
Interest Rs m029 0.0%   
Profit before tax Rs m1,1021,412 78.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-4 0.0%   
Extraordinary Inc (Exp) Rs m0-35 0.0%   
Tax Rs m343293 117.3%   
Profit after tax Rs m7591,080 70.2%  
Gross profit margin %10.812.3 88.1%  
Effective tax rate %31.120.7 150.3%   
Net profit margin %7.28.1 89.3%  
BALANCE SHEET DATA
Current assets Rs m6,4105,979 107.2%   
Current liabilities Rs m8,8282,432 363.0%   
Net working cap to sales %-23.026.6 -86.7%  
Current ratio x0.72.5 29.5%  
Inventory Days Days5863 91.5%  
Debtors Days Days3860 63.6%  
Net fixed assets Rs m1,4066,403 22.0%   
Share capital Rs m166182 91.4%   
"Free" reserves Rs m6,2869,293 67.6%   
Net worth Rs m6,4559,548 67.6%   
Long term debt Rs m0230 0.0%   
Total assets Rs m8,82812,843 68.7%  
Interest coverage xNM50.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.21.0 114.4%   
Return on assets %8.68.6 99.5%  
Return on equity %11.811.3 103.9%  
Return on capital %17.114.3 119.1%  
Exports to sales %8.329.2 28.3%   
Imports to sales %21.06.3 331.7%   
Exports (fob) Rs m8693,900 22.3%   
Imports (cif) Rs m2,209847 260.9%   
Fx inflow Rs m9594,356 22.0%   
Fx outflow Rs m2,6121,162 224.7%   
Net fx Rs m-1,6533,194 -51.8%   
CASH FLOW
From Operations Rs m1,0701,119 95.6%  
From Investments Rs m-750-853 87.9%  
From Financial Activity Rs m-150-334 44.8%  
Net Cashflow Rs m171-68 -250.2%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 15.1 120.5%  
FIIs % 1.0 3.0 33.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 31.7 91.8%  
Shareholders   28,591 20,176 141.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS